Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe
{{output}}
Background: This study aims to compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) for lumi... ...
